Don’t fall under the digital bus. That’s how Gartner’s 2016 report characterizes the certainty and velocity of the movement to digital. And, according to IDC, two-thirds of CEOs plan to focus on digital transformation strategies in 2016. No doubt that many life sciences company CEOs will be among those on the digital bus.
As market researchers, we have spent a lot of time listening to what patients and caregivers want and do not want when it comes to pharmaceutical websites. From the very big to the very small, here is a list of suggestions from consumers on how to increase a pharmaceutical branded website’s potential.
At the end of June 2016, Omnicom Health Group announced the launch of DDB Health. The new organization combines the former AgencyRx, Flashpoint Medica, Synergy, and DDB Health Germany and DDB Health Paris into a single organization.
It’s no secret that marketing has grown in complexity in the last few decades, coupled with the rise in digital technologies. Unless you’ve been completely disconnected, you likely know that the newest phenomenon in this world is Pokémon Go, an app-based game that has single-handedly taken over the technological world.
One of the most critical questions marketers ask is, How are expectations changing? Those shifts in what earns time and attention have prompted us to evolve – even radically change – how we engage consumers. But what about physicians?
It takes lots of fresh ingredients to cook up a successful marketing agency. Talent. Relationships. Courage. A positive culture. Strong, committed leadership. Mentorship. Strategic vision. A willingness to innovate. The ability to stay awake for 48 consecutive hours. And plenty more. One other ingredient, though, doesn’t often get the attention that we feel it should. It may in fact be just as critical as all the others to an agency’s long-term success, but by its nature can often sink into the background. Social responsibility.
Side effects may include generalized paragraph counting, occasional moral discomfort, reference anxiety, and recurring dreams of side effect reels on loop.
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, will retire as president and CEO and from the company effective Dec. 31, 2016.
Grünenthal Group named Gabriel Baertschi to become the company’s new CEO as of Oct. 1, 2016.
Alicia Secor has been named president and CEO of Juniper Pharmaceuticals Inc., effective Aug. 1, 2016. Secor will also be appointed to the board of directors.
